9 Oct 2007 ... Pharsight Signs New Customer for WinNonlin® AutoPilot™. Global Specialty
Pharmaceutical Company Plans Deployment of New PK Analysis.
Contacts: Investors EVC Group Douglas Sherk, 415-896-6820 Jennifer Beugelmans, 646-201-5447
Media EVC Group Jen Saunders 646-201-5431
FOR IMMEDIATE RELEASE
Pharsight Signs New Customer for WinNonlin® AutoPilot™ Global Specialty Pharmaceutical Company Plans Deployment of New PK Analysis Automation Software, Expands Use of Pharsight’s Software Portfolio MOUNTAIN VIEW, Calif., October 9, 2007 – Pharsight Corporation (OTC Bulletin Board:PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that a global specialty pharmaceutical company has licensed its recently released WinNonlin AutoPilot software. The WinNonlin AutoPilot license agreement is the second Pharsight has closed with leading pharmaceutical companies. WinNonlin AutoPilot is a configurable software application for WinNonlin®, Pharsight’s industry standard pharmacokinetic/pharmacodynamic (PK/PD) modeling and analysis software that automates the production of clinical PK analyses from study data to be used in standard reports. Under the terms of the license agreement, Pharsight’s customer has also purchased the IVIVC Toolkit™ for WinNonlin® and expanded its use of Pharsight’s portfolio of PK/PD analysis and data management tools, including WinNonlin, WinNonlin Validation Suite™, Pharsight Knowledgebase Server™ (PKS™), PKS Validation Suite™, and PKS Reporter™. The customer is the third leading global pharmaceutical company that has purchased additional PKS licenses this year. "We believe that our customer’s decision to leverage its investment in WinNonlin with the purchase of WinNonlin AutoPilot illustrates how companies are utilizing their information technology investments to increase and support research and development productivity,” said Shawn O’Connor, president and chief executive officer of Pharsight. “We also continue to see our installed base expand its use of PKS and purchase additional Pharsight products, and we believe this is indicative of the pharmaceutical industry’s increased adoption of modeling as a means to make the drug development process more predictable. Pharsight is committed to expanding its market leadership in PK/PD data management by continuing to work with leading pharmaceutical companies that recognize the importance of information technology to enable compliant and productive analyses, reporting and data management workflows.”
About WinNonlin AutoPilot WinNonlin AutoPilot orchestrates PK analyses by selecting input data from a user’s local file system or PKS, and then directs WinNonlin to perform analyses and produce report-quality tables, figures, and text output (e.g., in Microsoft ® Excel, SigmaPlot®, and Microsoft® Word) for regulatory submissions and interim reports. Formatted PK analyses outputs reflect the requirements and SOPs of each research organization, and WinNonlin AutoPilot provides a user-interface that allows extensive configuration of formatting and business rules to enable clear communication of standards and immediate use across the organization. PK analyses that can be automated include noncompartmental analysis for various study designs and inferential statistics (e.g., bioequivalence testing), as well as comparisons between analytes, dose routes or other conditions. Used in conjunction with PKS and PKS Reporter, WinNonlin AutoPilot provides standardized, regulatory-compliant, secure and automatic generation of routine analyses and reports. Used independently of PKS and PKS Reporter, WinNonlin AutoPilot can provide significant return on investment through productivity gains and quality improvements in PK analysis and reporting. About Pharsight Corporation Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com. Forward Looking Statements The statements in this press release related to the performance, benefit and potential market size of Pharsight’s products, services and technology are forward looking statements. Forwardlooking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations and customers failing to perceive the benefits of Pharsight products to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on August 13, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.
Registered Trademarks and Trademarks Pharsight, WinNonlin, WinNonlin AutoPilot, WinNonlin Validation Suite, IVIVC Toolkit for WinNonlin, Pharsight Knowledgebase Server, PKS, PKS Reporter, and PKS Validation Suite are trademarks or registered trademarks of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.
